trial

Control of Metabolic and Cardiovascular Risk in Patients With Schizophrenia and Overweight

NCTId NCT00584519
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase — · Completed
Enrollment 430 (actual)
Sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Primary completion 2009-06
Synthesized from structured facts only — each point cited above.

Design & status

Phase
—
Status
Completed
Enrollment
430 (actual)
Study type
Observational
Allocation
—
Model
—
Masking
—
Start
2007-06
Primary completion
2009-06
Eligibility
ALL · 18 Years

Interventions & indications

Drugs
non-interventional

Sponsors

Pfizer's Upjohn has merged with Mylan to form Viatris Inc.Lead Sponsor

Sites

0 total

Facts & assertions

4 sourced
Enrollment
430
Phase
NA
Primary Completion Date
2009-06
Status
COMPLETED
relationships
The graph out of here
drug
non-interventional
drug
lead_sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
company
indication
Schizophrenia
indication
Obesity
indication
Schizophrenia
indication